If you made any changes in Pure these will be visible here soon.

Personal profile

Ancillary activities

  • AM Pharma Bunnik | Bunnik | Pres. Commissaris | 2012-02-08 - present
  • AcTI Technologie en innovatie | Onbekend | Lid | 2012-02-08 - present
  • Artemis Foundation | Onbekend | Cofounder/Dir. | 2012-02-08 - present
  • Dynomics BV Rotterdam | Rotterdam | Commissaris | 2012-02-08 - present
  • Erasmus Universiteit | Rotterdam | Directeur | 2012-02-08 - present
  • Erasmus Universiteit Hope BV | Rotterdam | Commissaris | 2012-02-08 - present
  • Erasmus Universiteit ISAM BV | Rotterdam | Pres. Commissaris | 2012-02-08 - present
  • ErasmusMC, afdeling Virologie | Rotterdam | Hoogleraar | 2012-02-08 - present
  • Gezondheidsraad | Onbekend | Lid | 2012-02-08 - present
  • Medical Delta Multiplier BV | Delft/Leiden/Rotterdam | Oprichter/Dir. | 2012-02-08 - present
  • Medifocus Lelystad | Leystad | Directeur | 2012-02-08 - present
  • SAB Forbion Caital Partners | Onbekend | Lid | 2012-02-08 - present
  • SAB Probiotics Pfizer Consumer Health | Onbekend | Voorzitter | 2012-02-08 - present
  • Stichting Darmgezondheid | Onbekend | Oprichter/Dir. | 2012-02-08 - present
  • Viroclinics Biosciences BV | Rotterdam | Commissaris | 2012-02-08 - present

Ancillary activities are updated daily

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 3 Similar Profiles
Probiotics Medicine & Life Sciences
probiotics Agriculture & Biology
Vaccines Medicine & Life Sciences
Synbiotics Medicine & Life Sciences
Research Medicine & Life Sciences
vaccines Agriculture & Biology
Microbiota Medicine & Life Sciences
Industry Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

Policies and patenting to stimulate the biotechnology sector: Evidence from the Netherlands

Van Dongen, P., Tak, H. & Claassen, E., 1 Feb 2019, In : Science and Public Policy. 46, 1, p. 136-147 12 p.

Research output: Contribution to JournalArticleAcademicpeer-review

biotechnology
patent
Netherlands
evidence
policy

Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective

van der Waal, M. B., Flach, J., Browne, P. D., Besseling-van der Vaart, I., Claassen, E. & van de Burgwal, L. H. M., Mar 2019, In : PharmaNutrition. 7, p. 1-14 14 p., 100139.

Research output: Contribution to JournalArticleAcademicpeer-review

colitis
Probiotics
quality of life
Ulcerative Colitis
probiotics

Towards a rational design of faecal transplant analogues

Larsen, O. F. A., Koning, A. H. J., van der Spek, P. J. & Claassen, E., 3 Apr 2019, In : Scientific Reports. 9, p. 1-6 6 p., 5558.

Research output: Contribution to JournalArticleAcademicpeer-review

Safety
Microbiota
Costs and Cost Analysis
Therapeutics
Fecal Microbiota Transplantation
Open Access
product development
Microbiota
Probiotics
Industry
Public-Private Sector Partnerships

A research agenda to reinforce rabies control: A qualitative and quantitative prioritization

Neevel, A. M. G., Hemrika, T., Claassen, E. & van de Burgwal, L. H. M., 4 May 2018, In : PLoS Neglected Tropical Diseases. 12, 5, e0006387.

Research output: Contribution to JournalArticleAcademicpeer-review

Open Access
Rabies
Research
Mass Vaccination
Rabies Vaccines
Rabies virus